(a) declaring that any food or drug or class of food or drugs is adulterated if any prescribed substance or class of substances is present therein or has been added thereto or extracted or omitted therefrom;
(a.01) declaring that any drug is adulterated if the Minister believes that a prescribed substance contained in that drug presents a serious risk to the environment;
(a.1) respecting consultations in respect of orders referred to in section 2.4;
(b) respecting
(i) the labelling and packaging and the offering, exposing and advertising for sale of food, drugs, cosmetics and devices,
(ii) the size, dimensions, fill and other specifications of packages of food, drugs, cosmetics and devices,
(iii) the sale or the conditions of sale of any food, drug, cosmetic or device, and
(iv) the use of any substance as an ingredient in any food, drug, cosmetic or device,
to prevent the purchaser or consumer thereof from being deceived or misled in respect of the design, construction, performance, intended use, quantity, character, value, composition, merit or safety thereof, or to prevent injury to the health of the purchaser or consumer;
(b.01) respecting, for the purposes of managing risks to the environment, any of the following:
(i) the labelling and packaging and the offering, exposing and advertising for sale of food, drugs, cosmetics and devices,
(ii) the size, dimensions, fill and other specifications of packages of food, drugs, cosmetics and devices,
(iii) the sale or the conditions of sale of any food, drug, cosmetic or device, and
(iv) the use of any substance as an ingredient in any food, drug, cosmetic or device;
(b.1) respecting the conduct of clinical trials;
(b.2) respecting the issuance of authorizations referred to in section 3.1 and the amendment, suspension and revocation of those authorizations;
(b.3) authorizing the Minister to impose terms and conditions on authorizations referred to in section 3.1, including existing authorizations, and to amend those terms and conditions;
(b.4) requiring the Minister to ensure that decisions with regard to the issuance, amendment, suspension and revocation of authorizations referred to in section 3.1, and to the imposition and amendment of terms and conditions referred to in paragraph (b.3), along with the reasons for those decisions, are publicly available;
(b.5) requiring holders of an authorization referred to in section 3.1, or former holders of such an authorization, to provide the Minister, after the clinical trial to which the authorization relates is completed or discontinued or, if the authorization is suspended or revoked, after the suspension or revocation, with safety information that the holders or former holders receive or become aware of about the drug, device or food for a special dietary purpose that is or was the subject of the clinical trial;
(c) prescribing standards of composition, strength, potency, purity, quality or other property of any article of food, drug, cosmetic or device;
(d) respecting the importation of food, drugs, cosmetics and devices — including any importation that is solely for the purpose of export — in order to ensure compliance with the provisions of this Act and the regulations;
(e) respecting the method of manufacture, preparation, preserving, packaging, storing and testing of any food, drug, cosmetic or device in the interest of, or for the prevention of injury to, the health of the purchaser or consumer or to manage risks to the environment;
(f) requiring persons that sell food, drugs, cosmetics or devices, or persons that import them solely for the purpose of export, to maintain any records, reports, electronic data or other documents that the Governor in Council considers necessary for the purposes of this Act;
(g) respecting the form and manner of the Minister’s indication under section 12, including the fees payable therefor, and prescribing what premises or what processes or conditions of manufacture, including qualifications of technical staff, shall or shall not be deemed to be suitable for the purposes of that section;
(h) requiring manufacturers of any drugs described in Schedule E to submit test portions of any batch of those drugs and respecting the form and manner of the Minister’s indication under section 13, including the fees payable therefor;
(h.01) respecting the provision to the Minister of evidence under subsection 16.3(2);
(h.1) respecting the establishment by the Minister of the list referred to in subsection 29.1(1), including amendments to it;
(i) respecting the powers, duties and functions of inspectors and analysts and the taking of samples;
(i.1) respecting the seizure, detention, forfeiture and disposition of articles under this Act;
(j) exempting, with or without conditions, any food, drug, cosmetic, device, person or activity from all or any of the provisions of this Act or the regulations;
(j.1) respecting orders referred to in sections 30.01, 30.02, 30.05 and 30.06;
(k) prescribing forms for the purposes of this Act and the regulations;
(k.1) respecting the time and manner in which information, notices and documents are to be provided or served under this Act;
(k.2) requiring persons to provide information to the Minister in respect of food, drugs, cosmetics or devices — or in respect of activities related to food, drugs, cosmetics or devices — in circumstances other than those provided for in this Act and authorizing the Minister to determine the information to be provided and the time and manner in which it is to be provided;
(l) providing for the analysis of food, drugs or cosmetics other than for the purposes of this Act and prescribing a tariff of fees to be paid for that analysis;
(l.1) respecting the assessment of the effect on the environment or on human life and health of the release into the environment of any food, drug, cosmetic or device, and the measures to take before importing or selling any such food, drug, cosmetic or device;
(m) adding anything to any of the schedules, other than to Schedule A or G, in the interest of, or for the prevention of injury to, the health of the purchaser or consumer, or deleting anything from any of the schedules, other than from Schedule A or G;
(n) respecting the distribution or the conditions of distribution of drugs as samples;
(o) respecting
(i) the method of manufacture, preparation, preserving, packing, labelling, storing and testing of any new drug, and
(ii) the sale or the conditions of sale of any new drug,
and defining for the purposes of this Act the expression new drug;
(p) authorizing the advertising to the general public of contraceptive devices and drugs manufactured, sold or represented for use in the prevention of conception and prescribing the circumstances and conditions under which, and the persons by whom, those devices and drugs may be so advertised;
(q) defining agricultural chemical, food additive, mineral nutrient, veterinary drug and vitamin for the purposes of this Act;
(r) [Repealed, 2024, c. 17, s. 325]
(s) respecting the implementation, in relation to any food, drug, cosmetic or device, of international agreements that affect them; and
(t) prescribing anything that by this Act is to be prescribed.